Articles by Ben Comer - Pharmaceutical Executive

ADVERTISEMENT

Articles by Ben Comer

Ben Comer

Entourage disconnected

Articles
FDA Abroad
July 21, 2014

FDA officials willing to relocate to far-flung global cities should be congratulated for their herculean efforts to protect American patients. But funding cuts hamper the Agency's international presence.

WebMD: The Patient Value Equation
July 10, 2014

WebMD CEO David Schlanger tells PharmExec how connecting patients with physicians through a robust digital platform can deliver quality of care, cost savings, and better health outcomes.

Promoting Adherence: From Force to Finesse
June 16, 2014

Non-adherence, in the US alone, is a $100-billion-a-year problem. Healthcare players are touting patient education and engagement as the keys to better adherence rates. Ben Comer reports.

Immunotherapies: The New Hope for Cancer Treatment
June 9, 2014

The Cancer Research Institute is clearing a path to the future of immunotherapeutics. Ben Comer speaks to its CEO and director of scientific affairs, Jill O'Donnell-Tormey

Brands of Yesteryear: Where Are They Now?
May 6, 2014

We check back with previous Pharm Exec Brand of the Year winners to see how things are going.

2014 Brand of the Year
May 1, 2014

Pharm Exec's Brand of the Year recipients for 2014 are multiple sclerosis treatment Copaxone and KORLYM for diseases driven by excess production of the metabolic hormone, cortisol. We profile the journey of both drugs.

Sickle Cell Disease In Three Acts
April 22, 2014

Ben Comer reports on how new pipeline therapies, public research investments, and a renewed sociopolitical focus are working toward a happier outcome for sickle cell disease patients.

The Active Patient: Faces Of Change
February 1, 2014

Advocacy organizations and individual patients are getting more involved in every facet of the healthcare system, from drug R&D, to federal and state policy all fueled by the hour-to-hour passion of living with a disease.

Biosimilars or Bust
January 21, 2014

Where are the biosimilars to help cut costs as the first wave of biologics, or complex, small molecule respiratory drugs, for example, go off patent? They've arrived in Europe, but the U.S. lags...

ADVERTISEMENT

Click here